You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
據報內地首款國產新冠口服藥每瓶定價270人幣
《澎湃新聞》引述復星醫藥(02196.HK)消息指出,復星醫藥聯合真實生物緊急調配抗新冠肺炎小分子口服藥物阿茲夫定片,近日已陸續運抵河南、海南及新疆等地。按照各地醫保掛網價格,阿茲夫定片定價每瓶270元人民幣(下同),每瓶35片,每片1毫克,相較於目前已上市的新冠治療藥物,阿茲夫定片價格具有較大優勢。 根據國家衛健委辦公廳、國家中醫藥局辦公室發布通知,日前將該藥納入《新型冠狀病毒肺炎診療方案(第九版)》,列明阿茲夫定片用於治療普通型新冠肺炎成年患者,用法用量為空腹整片吞服,每次5毫克,每日一次,療程最多不超過14天。 如按照上述用法用量以及每片劑量,即患者每天需要服用5片阿茲夫定片,14天治療需要服用70片,即兩盒的用量,所需費用540元。 阿茲夫定片是首個國產新冠口服藥,也是內地首個獲批的擁有完全自主知識產權、並具有全球專利的1.1類抗新冠肺炎小分子口服藥物。 真實生物本月已經向港交所(00388.HK)提交IPO申請文件。中金公司為獨家保薦人。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account